A new standard is poised to transform melanoma care in terms of both patient outcomes and economics. Results from the phase 3 NADINA trial (Abstract LBA2), presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that a six-week course of neoadjuvant immunotherapy was superior to two years of adjuvant immunotherapy in treating macroscopic, resectable stage III melanoma.
2024
Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma
Bristol Myers Squibb (BMS) has announced that its new immunotherapy combination, Opdualag (nivolumab-relatlimab), has been accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for advanced melanoma.
First-of-its-kind clinical trial eliminates or shrinks melanoma tumors in 70% of patients
A clinical trial has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants.
Skin cancer the focus of new pharma campaign
While the rates of many cancer types are projected to continue to decrease, melanoma remains a notable outlier. In fact, Merck Canada says the number of Canadians receiving a diagnosis of melanoma each year continues to rise, more than tripling in the past 30 years.